Skip to content

BridgeBio Pharma BBIO Investment Proceeds

Investment Proceeds at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$752.82M+52.2%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$767.28M+886%
Royalty Pharma logo
Royalty PharmaRPRX
$4.32M-65.7%
Arrowhead Research logo
Arrowhead ResearchARWR
$115.34M-2.4%
Biogen logo
BiogenBIIB
$500K
Viatris logo
ViatrisVTRS

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's investment proceeds?
BridgeBio Pharma (BBIO) reported investment proceeds of $10M in Q1 2026.
What does investment proceeds mean?
Cash received from selling or maturing financial investments.
How do you interpret investment proceeds?
High inflows suggest the company is liquidating assets to support cash requirements or rebalancing its investment portfolio.
How does investment proceeds compare across companies?
Varies based on the company's cash management cycle and liquidity needs.